Burning Rock Biotech - BNR Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Burning Rock Biotech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Burning Rock Biotech stock.
View analyst ratings for Burning Rock Biotech or view top-rated stocks.

Burning Rock Biotech's stock was trading at $9.53 on January 1st, 2022. Since then, BNR shares have decreased by 63.2% and is now trading at $3.51.
View the best growth stocks for 2022 here.

Burning Rock Biotech saw a increase in short interest in July. As of July 15th, there was short interest totaling 909,700 shares, an increase of 70.9% from the June 30th total of 532,200 shares. Based on an average daily trading volume, of 823,100 shares, the days-to-cover ratio is currently 1.1 days. Approximately 1.1% of the shares of the company are short sold.
View Burning Rock Biotech's Short Interest.

Burning Rock Biotech is scheduled to release its next quarterly earnings announcement on Wednesday, August 31st 2022.
View our earnings forecast for Burning Rock Biotech.

Burning Rock Biotech will be holding an earnings conference call on Wednesday, August 31st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Burning Rock Biotech Limited (NASDAQ:BNR) posted its quarterly earnings data on Tuesday, May, 31st. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.16. The firm had revenue of $21.38 million for the quarter, compared to analysts' expectations of $19.99 million. Burning Rock Biotech had a negative net margin of 165.32% and a negative trailing twelve-month return on equity of 45.94%. During the same quarter last year, the firm posted ($0.25) EPS.

Burning Rock Biotech updated its FY 2022 earnings guidance on Tuesday, June, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $97.80 million-$97.80 million, compared to the consensus revenue estimate of $92.48 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Burning Rock Biotech investors own include Tiziana Life Sciences (TLSA), Teck Resources (TECK), Herman Miller (MLHR) and Immunic (IMUX).

(BNR) raised $196 million in an initial public offering on Friday, June 12th 2020. The company issued 13,500,000 shares at a price of $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen served as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers.

Burning Rock Biotech trades on the NASDAQ under the ticker symbol "BNR."

Burning Rock Biotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (1.69%), Sumitomo Mitsui Trust Holdings Inc. (0.72%), Nikko Asset Management Americas Inc. (0.72%) and Assenagon Asset Management S.A. (0.42%).

Shares of BNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BNR stock can currently be purchased for approximately $3.51.

Burning Rock Biotech (NASDAQ:BNR) has a market capitalization of $368.93 million and generates $79.69 million in revenue each year. The company earns $-125,020,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

Burning Rock Biotech employs 1,394 workers across the globe.

Burning Rock Biotech's mailing address is 601 BUILDING 3 STANDARD INDUSTRIAL UNIT2, GUANGZHOU F4, 510005. The official website for Burning Rock Biotech is www.brbiotech.com. The company can be reached via phone at 86-185-0164-1666.